Form 4: AngioDynamics SVP Granted Significant Equity Awards

AngioDynamics' SVP and Chief Legal Officer, Lawrence T. Weiss, was granted 30,900 restricted stock units and 30,900 performance rights on July 16, 2025, as part of his compensation.

Summary

• Lawrence T. Weiss, SVP, Chief Legal Officer of AngioDynamics Inc. (ANGO), acquired 30,900 shares of common stock and 30,900 performance rights on July 16, 2025.
• The common stock acquisition represents restricted stock units (RSUs) which vest in four equal annual installments starting July 16, 2026, through July 16, 2029.
• The performance rights are contingent on total shareholder return (TSR) relative to a peer group over a three-year period, with a potential payout ranging from 0% to 240% of the target number of shares.
• Following these transactions, Lawrence T. Weiss beneficially owns 83,597 shares of common stock and 30,900 performance rights.

Sentiment

Score: 7

Explanation: The document reports a routine executive equity grant, which is generally positive as it aligns management incentives with shareholder interests and promotes retention. There are no negative surprises or significant risks beyond the inherent market risks of equity compensation.

Positives

• The grant of equity awards aligns management's interests with shareholder value creation, particularly through performance-based vesting tied to Total Shareholder Return (TSR).
• The long-term vesting schedule for restricted stock units (four years) promotes retention of key executives.
• The potential for up to 240% payout on performance rights incentivizes strong company performance.

Negatives

• No immediate cash inflow for the executive from these grants, as they are equity awards with vesting conditions.
• The value of the performance rights is contingent on future company and peer group performance, introducing uncertainty.

Risks

• The value of the restricted stock units and performance rights is subject to the future market price of AngioDynamics' common stock.
• Performance rights may not vest or may vest at a lower percentage (down to 0%) if performance targets related to Total Shareholder Return (TSR) relative to a peer group are not met.
• Unvested shares will be forfeited if performance conditions are not met or if the executive leaves the company before vesting.

Future Outlook

The document indicates a long-term incentive structure for a key executive, with vesting periods extending to 2029 for restricted stock units and a three-year performance period for performance rights, suggesting a focus on sustained future performance and executive retention.

Management Comments

• The acquisition of 30,900 shares of common stock represents 30,900 restricted stock units, each of which represents a contingent right to receive one share of Common Stock.
• These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.
• Each performance right represents a contingent right to receive one share of Common Stock.
• Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee.

Industry Context

This type of equity grant, particularly with performance-based vesting tied to TSR, is a common practice in the medical technology and healthcare industry to align executive incentives with long-term shareholder value creation and competitive performance against peers. It reflects a standard approach to executive compensation in publicly traded companies.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) with multi-year vesting is a standard compensation practice across industries, including medical technology, for executive retention and long-term alignment.
• Performance-based equity awards tied to Total Shareholder Return (TSR) relative to a peer group are a common and increasingly preferred method for executive incentives, aligning with best practices in corporate governance to ensure pay-for-performance.
• The potential payout range of 0% to 240% for performance rights is within typical industry ranges for such awards, designed to reward exceptional performance while penalizing underperformance.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with shareholder value creation through performance-based equity.
• Employees: No direct impact mentioned, but a strong executive team incentivized by long-term performance can benefit overall company stability and growth.

Next Steps

• Monitoring the vesting of the restricted stock units on July 16, 2026, 2027, 2028, and 2029.
• Observing AngioDynamics' Total Shareholder Return (TSR) performance relative to its peer group over the three-year performance period for the performance rights.

Key Dates

Recommendation

Keywords

AngioDynamics, ANGO, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Performance Rights, Executive Compensation, Lawrence T. Weiss, Total Shareholder Return, TSR